Posted on 12/13/20
Syndax Closes Public Offering
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public . . .
Posted on 12/11/20
Forma Therapeutics Prices of Public Offering
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the pricing of an underwritten . . .
Posted on 12/11/20
Solid Biosciences Announces $90 Million Private Placement
CAMBRIDGE, Mass., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy . . .
Posted on 12/11/20
Biogen: Don't Give Up On This High Yielder
SummaryBiogen suffered a disappointing hit from the FDA advisory committee vote on aducanumab.Then the biopharma announced another $5.0 billion share repurchase plan.The stock offers an intriguing . . .
Posted on 12/11/20
Is Moderna Stock a Good Bet on Coronavirus Vaccines?
Moderna (NASDAQ:MRNA) is nearing the finish line in the coronavirus vaccine race. This biotech company has been among the leaders from the start. Back in March, . . .
Posted on 12/11/20
How Much Money Will Moderna Make From Its COVID Vaccine?
The countdown is on. One week from today, an FDA advisory committee will review Moderna's (NASDAQ:MRNA) emergency use authorization (EUA) filing for COVID-19 vaccine candidate mRNA-1273. . . .
Posted on 12/11/20
Forget Moderna! These 2 Stocks May be the Biggest Winners of the Vaccine Race
Since the beginning of the coronavirus vaccine race, we've been hearing a lot about Moderna (NASDAQ:MRNA). That's because back in March, the biotech company became the . . .
Posted on 12/11/20
What Could Keep the FDA From Green Lighting Pfizer's and Moderna's Vaccines?
Pfizer(NYSE:PFE) and Moderna(NASDAQ:MRNA) await critical FDA advisory committee reviews for their respective COVID-19 vaccine candidates over the next two weeks. The prospects that both vaccines win . . .
Posted on 12/10/20
Repligen Corp. Closes Public Offering of $312.2M
WALTHAM, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the closing of its previously announced underwritten public offering of an aggregate . . .
Posted on 12/10/20
Blue Cross Blue Shield of Massachusetts Awarded AIM's 2020 Sustainability Award
In recognition of its sustainability work and holistic approach to health, Blue Cross Blue Shield of Massachusetts (Blue Cross) has been awarded the 2020 Associated Industries . . .
Posted on 12/10/20
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease . . .
Posted on 12/10/20
Cities That Need the Most Initial Vaccinations Against COVID-19 – WalletHub Study
With frontline health care workers and other vulnerable populations like the elderly first in line to receive COVID-19 vaccinations, WalletHub today released its report on the . . .
Posted on 12/10/20
Faze Medicines Launches With $81 Million Series A
Faze Medicines, a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced its launch and Series A financing of $81 . . .
Posted on 12/10/20
Here's What Could Make Moderna's COVID Vaccine a Bigger Winner Than Pfizer's
We could be only days away from the first two emergency use authorizations (EUA) for COVID-19 vaccines in the U.S. An FDA advisory committee meets on . . .
Posted on 12/10/20
After Moderna and Pfizer, Which Vaccine Makers May Cross the Finish Line Next?
Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) are heading for the finish line in the coronavirus vaccine race. The U.S. Food and Drug Administration will meet with advisory . . .
Posted on 12/10/20
Is Biogen Getting Desperate?
Due to drastic measures being taken to stop the spread of the coronavirus, people around the world have had far less social interaction this year, which . . .
Posted on 12/10/20
Moderna Stock: Buy at the High?
Moderna (NASDAQ:MRNA) shares have soared by more than 768% this year. Right now, they're sitting at an all-time high. The clinical-stage biotech company was among the . . .
Posted on 12/10/20
Is Moderna Stock a Hold?
A recent downgrade from buy to hold from a Wall Street analyst has Moderna (NASDAQ:MRNA) stock under pressure. Needham analyst Alan Carr has removed his $110 . . .
Posted on 12/10/20
Nym Ranked Among Top 10 Most Promising Startups of 2020
Nym Health, the autonomous medical coding technology provider, ranked among the Top 10 Most Promising Startups of 2020, in a list released by Globes financial newspaper.Nym . . .
Posted on 12/9/20
EyePoint Pharmaceuticals Announces 1-for-10 Reverse Stock Split
WATERTOWN, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced . . .
Posted on 12/9/20
Sigilon Therapeutics Closes of Upsized IPO
CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (Nasdaq: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through . . .
Posted on 12/9/20
Thermo Fisher Doubles Global Footprint For Drug Development And Commercial Manufacturing
Thermo Fisher Scientific (NYSE:TMO) further expanded its footprint in North America and Europe for sterile drug product development and commercial manufacturing of critical medicines, therapies and . . .
Posted on 12/9/20
iSpecimen Seeks $20 Million In U.S. IPO Plan
SummaryiSpecimen has filed to raise $20 million in an IPO.The firm operates a human biospecimen online marketplace.ISPN has grown from a small revenue base and operates . . .
Posted on 12/8/20
Curis Announces Proposed Public Offering of Common Stock
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced its intention to offer and . . .
Posted on 12/8/20
Forma Therapeutics Launches Proposed Public Offering
WATERTOWN, MA--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that it has launched a . . .
Boston
